Clotting factor concentrates;Gerinnungsfaktorenkonzentrate

Hamostaseologie

Volumn 28, Issue 5, 2008, Pages 387-399

  Barthels, Monika ^a,c   Oldenburg, J ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c NONE   (Germany)

Author keywords

Abnormal bleeding; Clotting factor concentrates; Coagulation disorders; Haemophilias; Substitution therapy

Indexed keywords

ANBINEX; ANTITHROMBIN; ANTITHROMBIN III; ANTITHROMBIN III CONCENTRATE; BERININ; BERIPLEX; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; DROTRECOGIN; FANHDI; FIBRINOGEN; HAEMATE; HAEMOCOMPLETTON; HAEMOCTIN SDH; IMMUSEVEN; OCTANINE; OCTAPLAS; OCTAPLEX; OCTONATE; PROTEIN C; PROTEIN S; PROTHROMBIN; RECOMBINANT ANTITHROMBIN III; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; WILATE;

HUMAN; PLASMA; REVIEW; SUBSTITUTION THERAPY;

EID: 58149471439     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617186     Document Type: Review

References (31)

1. Abraham E, Laterre PF, Garg R et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-1341.
2. Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost 2004; 2: 861-862.
3. Astermark J. Treatment of the bleeding inhibitor patient. Semin Thromb Hemost 2003; 29: 77-85.
4. Barthels M, Sens B, Rienhoff O. Einführung: Probleme der Selbstbehandlung Hämophiler. 15. Hämophilie-Symposion. Berlin, Heidelberg: Springer 1986.
5. Barthels M, von Depka M. Gerinnungskompendium. Stuttgart: Thieme 2003.
6. Bernard GR, Vincent J-L, Laterre P-F et al. for the Recombinant Human Activated Pro-tein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein for severe sepsis. N Engl J Med 2001; 344: 699-709.
7. Bödeker B. Therapie. In: Brackmann HH, Schwaab R, Oldenburg J et al. Klinische Anwendung plasmatischer und rekombinanter Gerinnungsfaktoren. Bremen: Uni-Med 2003, 77-112.
8. Brackmann HH. Relevante Nebenwirkungen der Therapie. In: Brackmann HH, Schwaab R, Oldenburg J et al. Klinische Anwendung plasmatischer und rekombinanter Gerinnungsfaktoren. Bremen: Uni-Med 2003, 138-160.
9. Brackmann HH, Schwaab R, Oldenburg J et al. (Hrsg). Klinische Anwendung plasmatischer und rekombinanter Gerinnungsfaktoren. Bremen: Uni-Med 2003.
10. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor inhibitors - twenty years' "Bonn protocol". Vox Sang 1996; 70: 30-35.
11. Bundesärztekammer. Querschnittsleitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten. Kapitel 6. Schramm W. Oldenburg J. Faktor VIII-Konzentrate. Faktor VIII von Willebrand Faktor-Konzentrate, Faktor IX-Konzentrate, aktivierte Prothrombinkomplex-Konzentrate. 2009: 158-189.
12. DIN-Taschenbuch 261. Hämostaseologie Normen. E 58 939-1. Hämostaseologie - Referenzplasma: Teil 1: Anforderungen. Herstellung. Berlin, Wien, Zürich: Beuth 2002, 19-22.
13. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coag Fibrinol 1990; 1: 307-317.
14. Hellstern P, Köhler M, Müller-Berghaus G. Prothrombin complex concentrates, manufacture, clinical use and side effects. Thromb Res 1999: 95 Suppl 1.
15. Landbeck G, Kurme A. Regeln und Richtlinien zur Therapie der Hämophilie. Fortschr Med 1972; 90: 542-546.
16. Lechner K, Kyrle PA. Antithrombin III concentrates - are they clinically useful? Thromb Haemost 1995; 73: 340-348.
17. Lee M, Morfini M, Schulman S et al. and the factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. ISTH-Webside Publicat (21.03.2001).
18. Lusher J. Is the incidence and prevalence of inhibitors greater with recombinant products? No. J Thromb Haemost 2004; 2: 863-865.
19. Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: A review. Sem Thromb Hemost 29: 69-75.
20. Meili E. Ausgeprägte Blutungsneigungen durch angeborene Gerinnungsfaktor-Mängel und erworbene Inhibitoren. Hämostaseologie 2004; 24: 221-233.
21. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-386.
22. Offergeld R, Faensen D, Ritter S, Hamouda O. Human immundeficiency virus, hepatitis C, and hepatitis B infections among blood donors in germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Eurosurveillance 10; issues 1-3: 8-11.
23. Oldenburg J, Bartheis M. Angeborene Koagulopathien am Beispiel der Hämophilie A und B. Hemmkörperhämophilie. Hämostaseologie 2008; 28: 335-347.
24. Scharrer I. Rekombinanter Faktor VIIa (rFVIIa). In: Brackmann HH, Schwaab R, Oldenburg J et al. Klinische Anwendung plasmatischer und rekombinanter Gerinnungsfaktoren. Bremen: Uni-Med 2003, 135-138.
25. Schramm W. Konsensusempfehlungen zur Hämophiliebehandlung in Deutschland. Hämostaseologie 1994; 14: 81-83.
26. Schramm W (ed). Blood safety in the European Community: An Initiative for Optimal Use. European Commission Agreement Soc 98 201622 05F04, 1999.
27. Van den Berg M, Fischer K. Prophylaxis for severe hemophilia: Experience from Europe and the United States. Semin Thromb Hemost 2003; 29: 49-54.
28. Vincent J-L, Rrossaint R, Riou B et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Critical Care 2006, 10: R120 (doi:10.1186/cc5026).
29. Warren BL, Eid A, Singer P et al. High dose antithrombin III in severe sepsis. JAMA 2001; 286: 1869-1878.
30. Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfusion Med 2008; 18: 151-157.
31. White B, Livingstone W, Murphy C et al. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96: 3719-3724.